NCT07160790View on ClinicalTrials.gov

Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

September 2, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Non-erosive Gastroesophageal Reflux Disease
Interventions
DRUG

JP-1366 + placebo

taking JP-1366 + placebo

DRUG

Placebo + Placebo

taking placebo + placebo

Sponsors
All Listed Sponsors
lead

Onconic Therapeutics Inc.

INDUSTRY

NCT07160790 - Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease | Biotech Hunter | Biotech Hunter